Date: 2015-10-15
Type of information: Nomination
Compound:
Company: Nabriva Therapeutics (Austria)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 15, 2015, Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, announced the appointment Peter Wolf as General Counsel and Corporate Secretary, a newly created position. Mr. Wolf will be based at the company\'s U.S. headquarters in King of Prussia, PA. Peter Wolf most recently served as Senior Vice President, General Counsel and Corporate Secretary of Idera Pharmaceuticals, Inc. Prior thereto, Mr. Wolf held roles of increasing responsibility within the legal department of ViroPharma Incorporated, culminating in the role of Vice President, General Counsel and Corporate Secretary until its acquisition by Shire plc. While at ViroPharma, Mr. Wolf oversaw the legal aspects of business development activities, was responsible for corporate governance, securities and corporate matters, led the international expansion of the legal team, established a formal compliance program, and advised executive management and the board of directors. Prior to ViroPharma, Mr. Wolf was a corporate attorney at several law firms and practiced in the areas of corporate and securities law. Mr. Wolf received his J.D. from the George Washington University National Law Center and his Bachelor of Arts from the University of Delaware.
Financial terms:
Latest news:
